Cytokine Signalling Forum

Publications




Cytokine Signalling Forum: Single slide summaries – January 2022

Citera G \ Peterfy CG \ Pope JE \ Winthrop K L \ Bergman M \ Grimm SE \ Nash P \ Shamail GMH \ Strand V \ Uchio A. -

Upadacitinib as monotherapy or in combination with background MTX was effective in inhibiting the progression of structural joint damage through Week 48 in MTX-naïve and MTX‐inadequate responder patients with RA.

Recently approved in many countries for the treatment of RA, upadacitinib has been shown to significantly reduce the progression of structural joint damage in two Phase 3 studies (SELECT-EARLY and SELECT-COMPARE). In this analysis, Peterfy, et al. evaluated the progression of structural (radiographic) joint damage over 1 year in patients enrolled in these two upadacitinib RA studies.

Access original article via Pubmed

Upload date: January 2022

Article image